New combo therapy aims to shrink rectal tumors before surgery

NCT ID NCT06162650

Recruiting now Disease control Sponsor: National Cheng-Kung University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a total neoadjuvant therapy approach for stage II or III rectal cancer. Participants receive short-course radiotherapy followed by 9 cycles of mFOLFOX6 chemotherapy before any surgery. The goal is to see how many patients achieve a complete response, meaning no cancer remains detectable. The study is recruiting 42 adults in Taiwan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Short-course radiotherapy and mFOLFOX6 chemotherapy
What this could lead to: If successful, this approach could increase the chance of complete tumor disappearance before surgery, potentially reducing the need for more aggressive treatments.
What could go wrong: This is a small, early-phase study with only 42 participants, so results may not apply to all patients. Side effects from radiation and chemotherapy can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

National Cheng Kung University Hospital
RECRUITING

Tainan, 704, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.